Dentium Valuation

Is A145720 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A145720 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A145720 (₩69200) is trading below our estimate of fair value (₩226527.64)

Significantly Below Fair Value: A145720 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A145720?

Other financial metrics that can be useful for relative valuation.

A145720 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA4.9x
PEG Ratio0.4x

Price to Earnings Ratio vs Peers

How does A145720's PE Ratio compare to its peers?

The above table shows the PE ratio for A145720 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.8x
A336570 WON TECHLtd
17.7x37.9%₩503.0b
A041830 InBodyLtd
8.7x16.8%₩317.2b
A043150 Value Added Technology
6.4x12.4%₩338.7b
A287410 Jeisys Medical
34.4x29.6%₩960.9b
A145720 Dentium
6.3x15.6%₩596.8b

Price-To-Earnings vs Peers: A145720 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the peer average (16.8x).


Price to Earnings Ratio vs Industry

How does A145720's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: A145720 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the KR Medical Equipment industry average (14.4x).


Price to Earnings Ratio vs Fair Ratio

What is A145720's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A145720 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.3x
Fair PE Ratio15.7x

Price-To-Earnings vs Fair Ratio: A145720 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the estimated Fair Price-To-Earnings Ratio (15.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A145720 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩69,200.00
₩130,625.00
+88.8%
19.6%₩180,000.00₩100,000.00n/a8
Nov ’25₩69,000.00
₩130,625.00
+89.3%
19.6%₩180,000.00₩100,000.00n/a8
Oct ’25₩81,600.00
₩141,875.00
+73.9%
17.6%₩180,000.00₩100,000.00n/a8
Sep ’25₩79,900.00
₩148,125.00
+85.4%
13.1%₩180,000.00₩120,000.00n/a8
Aug ’25₩94,800.00
₩163,375.00
+72.3%
11.6%₩200,000.00₩140,000.00n/a8
Jul ’25₩112,900.00
₩171,625.00
+52.0%
8.6%₩200,000.00₩150,000.00n/a8
Jun ’25₩112,200.00
₩171,625.00
+53.0%
8.6%₩200,000.00₩150,000.00n/a8
May ’25₩129,900.00
₩171,625.00
+32.1%
8.6%₩200,000.00₩150,000.00n/a8
Apr ’25₩141,000.00
₩170,000.00
+20.6%
8.3%₩200,000.00₩150,000.00n/a8
Mar ’25₩144,200.00
₩170,000.00
+17.9%
8.3%₩200,000.00₩150,000.00n/a8
Feb ’25₩112,500.00
₩165,000.00
+46.7%
12.1%₩200,000.00₩130,000.00n/a8
Jan ’25₩131,000.00
₩167,222.22
+27.7%
11.9%₩200,000.00₩130,000.00n/a9
Dec ’24₩125,500.00
₩167,222.22
+33.2%
11.9%₩200,000.00₩130,000.00n/a9
Nov ’24₩113,800.00
₩174,375.00
+53.2%
15.3%₩200,000.00₩130,000.00₩69,000.008
Oct ’24₩106,900.00
₩183,111.11
+71.3%
9.3%₩200,000.00₩140,000.00₩81,600.009
Sep ’24₩122,300.00
₩185,333.33
+51.5%
9.6%₩200,000.00₩140,000.00₩79,900.009
Aug ’24₩148,200.00
₩181,875.00
+22.7%
9.7%₩200,000.00₩140,000.00₩94,800.008
Jul ’24₩145,000.00
₩181,875.00
+25.4%
9.7%₩200,000.00₩140,000.00₩112,900.008
Jun ’24₩173,600.00
₩167,777.78
-3.4%
17.4%₩200,000.00₩120,000.00₩112,200.009
May ’24₩143,900.00
₩150,555.56
+4.6%
17.3%₩200,000.00₩120,000.00₩129,900.009
Apr ’24₩139,700.00
₩135,000.00
-3.4%
10.8%₩160,000.00₩120,000.00₩141,000.009
Mar ’24₩121,000.00
₩123,777.78
+2.3%
6.9%₩145,000.00₩114,000.00₩144,200.009
Feb ’24₩114,500.00
₩123,777.78
+8.1%
6.9%₩145,000.00₩114,000.00₩112,500.009
Jan ’24₩100,000.00
₩124,250.00
+24.3%
7.2%₩145,000.00₩114,000.00₩131,000.008
Dec ’23₩88,300.00
₩120,444.44
+36.4%
11.4%₩145,000.00₩90,000.00₩125,500.009
Nov ’23₩76,700.00
₩125,000.00
+63.0%
15.4%₩160,000.00₩90,000.00₩113,800.008

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies